Abstract: Lazertinib (YH25448) is a highly selective, third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for the treatment of advanced non-small cell lung cancer (NSCLC). Designed to overcome resistance to first- and second-generation EGFR-TKIs, lazertinib potently targets both sensitizing EGFR mutations (Ex19del, L858R) and the T790M gatekeeper resistance mutation while sparing wild-type EGFR. Recent pivotal clinical trials, notably LASER301 and MARIPOSA, have established lazertinib as a formidable first-line therapy for EGFR-mutated advanced NSCLC, both as a monotherapy and in combination with the bispecific antibody amivantamab. The combination regimen has demonstrated unprecedented progression-free survival (PFS) benefits, shifting the treatment paradigm beyond single-agent osimertinib. This review comprehensively analyzes the pharmacological activity, molecular mechanisms, structure-activity relationships (SAR), current clinical limitations, and future perspectives of lazertinib in the first-line treatment of advanced NSCLC.
1. Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the standard of care for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR activating mutations, such as exon 19 deletions (Ex19del) and exon 21 L858R point mutations [2][4]. However, the inevitable emergence of acquired resistance to first-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) TKIs, primarily driven by the EGFR T790M gatekeeper mutation, necessitated the development of third-generation inhibitors [2][3].
Lazertinib (also known as YH25448, LECLAZA®, or Lazcluze®) is an oral, brain-penetrant, third-generation EGFR-TKI co-developed by Yuhan Corporation and Janssen Biotech [1][2]. It received its first global approval in the Republic of Korea in January 2021 for patients with EGFR T790M mutation-positive NSCLC who had progressed on prior EGFR-TKI therapy [2]. More recently, lazertinib has moved to the forefront of NSCLC management. In August 2024, the US Food and Drug Administration (FDA) approved the combination of lazertinib and the EGFR/c-MET bispecific antibody amivantamab for the first-line treatment of NSCLC with EGFR-sensitive mutations, marking a significant milestone in overcoming the limitations of existing monotherapies like osimertinib [1][3][14].
2. Pharmacological Activity
Lazertinib has demonstrated robust pharmacological activity and superior clinical efficacy in multiple landmark trials. Pharmacokinetically, lazertinib is widely distributed in the body, highly protein-bound (99.1–99.7%), and exhibits a mean terminal half-life of 64.7 hours, allowing for once-daily oral dosing (240 mg) [2]. It also possesses high blood-brain barrier (BBB) permeability, achieving significant intracranial tumor regression [2].
In the first-line setting, the phase 3 LASER301 study compared lazertinib monotherapy against gefitinib in treatment-naïve patients with EGFR-mutated advanced NSCLC. Lazertinib significantly extended the median PFS to 20.6 months compared to 9.7 months for gefitinib (HR 0.45, P < 0.001) [1][8]. Notably, network meta-analyses have suggested that lazertinib provides the greatest PFS benefit among TKIs specifically for patients harboring the L858R mutation [11], and it has shown promising overall survival (OS) improvements [9].
The therapeutic landscape was further transformed by the phase 3 MARIPOSA trial, which evaluated the combination of lazertinib and amivantamab versus osimertinib monotherapy in previously untreated patients. The combination therapy achieved a significantly longer median PFS of 23.7 months compared to 16.6 months for osimertinib (HR 0.70, P < 0.001) [1][5][7]. The combination also demonstrated a clinically meaningful improvement in OS (median 47.5 vs. 37.6 months) and strong intracranial efficacy, with a central nervous system (CNS) PFS of 24.9 months [7][13]. Additional studies, such as CHRYSALIS and CHRYSALIS-2, have confirmed the durable antitumor activity of this combination in both treatment-naïve and osimertinib-relapsed settings, including efficacy against atypical EGFR mutations [3][10].
3. Molecular Mechanism of Action
Lazertinib is a highly selective, irreversible EGFR-TKI. It exerts its mechanism of action by covalently binding to the kinase domain of mutant EGFR, thereby inhibiting downstream signaling pathways, including the phosphorylation of EGFR, AKT, and ERK [2]. This inhibition induces apoptosis in EGFR-mutant lung cancer cells, evidenced by an increase in cleaved Bim-EL protein and the activation of caspase 3/7 [2].
A critical feature of lazertinib is its mutant selectivity; it potently targets single activating mutations (Ex19del, L858R) and double mutations (Ex19del/T790M and L858R/T790M) while exhibiting significantly less activity against wild-type (WT) EGFR compared to earlier generation TKIs [2]. When used in combination with amivantamab, the regimen employs a dual-inhibition strategy: lazertinib targets the intracellular catalytic domain of EGFR, while amivantamab binds to the extracellular domains of both EGFR and MET. This synergistic mechanism not only blocks ligand binding and promotes receptor degradation but also recruits immune effector cells and proactively targets MET amplification—a primary EGFR-independent resistance mechanism [4][13].
4. Structure-Activity Relationship (SAR)
The superior medicinal chemistry profile of lazertinib is rooted in its unique structural design, which deliberately improves upon the scaffold of osimertinib. Lazertinib differs from osimertinib by featuring a 4-phenyl-3-dimethylaminomethyl-1-pyrazole group that replaces the indole ring on the pyrimidine core, and a morpholine group substituting the dimethylaminoethyl-N-methyl chain at the 2-position of the phenyl ring [1].
The structural basis for lazertinib's high selectivity against the T790M gatekeeper mutation is enabled by this substituted pyrazole moiety. The combination of a hydrophobic phenyl group and a hydrophilic, H-bond-donating amine on the pyrazole facilitates optimal van der Waals and hydrogen-bonding interactions within the mutant EGFR kinase domain [3]. Time-dependent kinetic studies and X-ray cocrystal structures reveal that this unique methyleneamine rigidifies the pyrazole into a conformation that weakens binding to WT EGFR (reducing off-target toxicity) while maintaining potent, irreversible covalent bonding to the C797 residue in L858R and T790M mutants [3].
5. Current Limitations
Despite its clinical success, the use of lazertinib is accompanied by limitations regarding acquired resistance and toxicity. Like other third-generation irreversible TKIs, lazertinib is vulnerable to the acquired tertiary C797S mutation, which alters the cysteine residue required for the drug's potency-enabling covalent bond, rendering the inhibitor ineffective [3]. Off-target resistance mechanisms also emerge, including MET amplification, PIK3CA alterations, and ERBB2 mutations [2].
Toxicity is another significant consideration. As a monotherapy, lazertinib is generally well-tolerated, with common adverse events (AEs) including rash, itchiness, paresthesia, and muscle spasms [2]. However, the highly efficacious first-line combination of lazertinib and amivantamab comes with a steep increase in toxicity. In the MARIPOSA trial, 75% of patients receiving the combination experienced grade 3 or higher treatment-related AEs, compared to 43% in the osimertinib arm [6][13]. The combination is frequently associated with severe rash, paronychia, hypoalbuminemia, and high rates of infusion-related reactions (IRRs) and venous thromboembolic events [13]. This "time toxicity" and increased AE burden require careful patient selection and proactive management [13].
6. Future Perspectives
The future trajectory for lazertinib involves mitigating its current limitations while expanding its clinical utility. To address the toxicity and administration burden of intravenous amivantamab, ongoing phase 3 trials (such as PALOMA-3) are evaluating a subcutaneous formulation of amivantamab in combination with lazertinib. Early results suggest this approach significantly reduces infusion-related reactions and improves patient convenience without compromising efficacy [3][8][13].
Furthermore, drug discovery efforts are pivoting toward advanced reversible ATP-competitive and allosteric inhibitors capable of overcoming the C797S mutation [3]. In the clinic, the paradigm is shifting toward a well-structured shared decision-making process. Oncologists must weigh the unprecedented PFS and OS benefits of the lazertinib-amivantamab combination against its heightened toxicity profile, tailoring first-line intensification strategies to high-risk subgroups (e.g., those with high tumor burden, baseline ctDNA positivity, or specific co-mutations) who truly stand to benefit from this aggressive approach [6][13].
